Study for Patients With Non Small Cell Lung Cancer (NSCLC)
- Sponsor
- Charite University, Berlin, Germany
- Study ID
- NCT00168883
- Phase
- PHASE2
- Status
- Unknown
Conditions
- Carcinoma, Non-Small-Cell Lung
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Carboplatin — DRUG
- Paclitaxel — DRUG
- Vinorelbine — DRUG
Study Details
This is a randomized study to assess the efficacy and safety of chemotherapy with platin compared to chemotherapy without platin.
Key Dates
- Start date
- Oct 31, 2002
- Status verified
- Sep 2006
- Completion
- Dec 31, 2006
Study Design
- Enrollment
- 80 participants
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Primary Outcome Measure
Determination of response rate (stable disease [SD] or better)
Central Contacts
- Ulrich Keilholz, MD+49-30-8445-3596
- Alexander Schmittel, MD+49-30-8445-3090
Related Studies
- Molecular Analysis of Thoracic MalignanciesEnrolling By Invitation · Stanford University · Stanford, California
- Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.Recruiting · University of Colorado, Denver · Aurora, Colorado
- KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)PHASE1/PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Gilbert, Arizona
- KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)Recruiting · Merck Sharp & Dohme LLC · Gilbert, Arizona